No Data
No Data
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
Spyre Therapeutics Poised for Market Leadership With Promising IBD Drug Candidates
Spyre Therapeutics to Participate in Upcoming Investor Conference
Spyre Therapeutics Files for $500M Mixed Securities Shelf
Express News | Spartan Resources Ltd Files for Mixed Shelf of up to $500 Mln - SEC Filing
Spyre Therapeutics Initiated at Outperform by Wedbush
No Data
No Data